A. Hugman

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

W. Boersma, S. Kahn, M. Kovacs, 2022, Research and practice in thrombosis and haemostasis.

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin

W. Boersma, S. Kahn, M. Kovacs, 2021, Research and practice in thrombosis and haemostasis.

Hepcidin: an important new regulator of iron homeostasis.

A. Hugman, 2006, Clinical and laboratory haematology.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

L. Campbell, J. Reynolds, J. Szer, 2015, The Lancet. Haematology.

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

J. Reynolds, J. Szer, C. Tiley, 2012, Blood.

All-trans-retinoic acid , idarubicin , and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia ( APML 4 )

J. Reynolds, J. Szer, C. Tiley, 2012 .

therapy in acute promyelocytic leukemia (APML4) -retinoic acid, idarubicin, and IV arsenic trioxide as initial trans All-

J. Reynolds, J. Szer, C. Tiley, 2013 .

Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study

G. Hankey, T. Brighton, S. Mcrae, 2023, Research and practice in thrombosis and haemostasis.